Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease
affecting both adults and children. Belimumab is the only biologic approved for SLE, and the …

Objective In systemic lupus erythematosus (SLE), disease activity and glucocorticoid (GC)
exposure are known to contribute to irreversible organ damage. We aimed to examine the …

Background Systemic lupus erythematosus (SLE) management objectives include
preventing disease flares while minimizing glucocorticoid exposure. Pooled data from the …

Disease modification has become a well-established concept in several therapeutic areas;
however, no widely accepted definition of disease modification exists for SLE. We reviewed …

Health disparities in the prevalence and outcomes of systemic lupus erythematosus (SLE)
are well documented across racial and ethnic groups. Similar to other chronic diseases …

Glucocorticoids (GCs) remain a cornerstone of the treatment of Systemic Lupus
Erythematosus (SLE). Numerous studies have emphasized the risk of damage accrual in …

Introduction: Systemic lupus erythematosus [SLE] is a chronic, autoimmune condition
characterized by the formation of autoantibodies directed against nuclear components and …

Organ damage is a key determinant of poor long‐term prognosis and early death in patients
with systemic lupus erythematosus (SLE). Prevention of damage is a key treatment goal of …

Systemic lupus erythematosus (SLE) is a complex and heterogeneous autoimmune disease.
A main challenge faced by clinicians is early identification of SLE, frequently resulting in …

Aim: Assess the comparative efficacy of anifrolumab 300 mg versus belimumab 10 mg/kg in
adults with moderate-to-severe systemic lupus erythematosus (SLE) receiving standard …